Cargando…
Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List
BACKGROUND: Evidence-based decision on drug list or formulary has been applied worldwide. Although the importance of scientific evidence was emphasized, the decision-making procedures for including medicines into the national reimbursement drug list were often challenged by their process opacity and...
Autores principales: | Liu, Wenbin, Shi, Lizheng, Sawhney, Monika, Gu, Xiaoli, Chen, Yingyao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369556/ https://www.ncbi.nlm.nih.gov/pubmed/30744609 http://dx.doi.org/10.1186/s12913-019-3937-0 |
Ejemplares similares
-
Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list
por: Liu, Liu, et al.
Publicado: (2022) -
Reporting quality of economic evaluations of the negotiated Traditional Chinese Medicines in national reimbursement drug list of China: A systematic review
por: Yan, Juntao, et al.
Publicado: (2023) -
How health technology reassessment can support disinvestment in China’s national drug reimbursement list
por: Shi, Lizheng, et al.
Publicado: (2023) -
Impact of delisting OTC medicines from reimbursement list
por: Chytilová, Petra, et al.
Publicado: (2015) -
Using the WHO Essential Medicines List to Assess the Appropriateness of Insurance Coverage Decisions: A Case Study of the Croatian National Medicine Reimbursement List
por: Jeličić Kadić, Antonia, et al.
Publicado: (2014)